Mer­ck­'s pneu­mo­coc­cal vac­cine suf­fers PDU­FA de­lay in pe­di­atric pop­u­la­tion, with Pfiz­er hot on its tail

Back in Ju­ly, Mer­ck’s pneu­mo­coc­cal vac­cine Vaxneu­vance got the seal of ap­proval from the FDA to treat adults, with an­a­lysts pre­dict­ing it could be a block­buster prod­uct and se­cure more than $1 bil­lion in peak sales. A few months lat­er in De­cem­ber, the FDA grant­ed Pri­or­i­ty Re­view for an sBLA for Vaxneu­vance to be po­ten­tial­ly in­di­cat­ed for mi­nors and in­fants.

And the fed­er­al agency gave the big phar­ma a PDU­FA date of April 1, 2022. But rather than come to a de­ci­sion Fri­day, the FDA in­stead pushed out the PDU­FA date by three months to Ju­ly 1.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER